AstraZeneca agreed in March agreed to pay up to $6.9 billion to work with Daiichi on the drug known as trastuzumab deruxtecan, in a direct challenge to Roche. The treatment, also known as DS-8201, demonstrated a clinically meaningful response in patients who have metastatic breast cancer and a type of protein on the surface of cancer cells, the two companies said on Wednesday. It targets the HER2 protein, a major trigger of uncontrolled cell growth in about 20 percent of breast cancers.
Comments